Clinical Data
Background: CMV in HSCT
HSCT patients are at increased risk for CMV infection, disease, and associated mortality1–4
Positive CMV serostatus pre-HSCT is a strong predictor of CMV infection and disease.1,2
- CMV infection has been shown to occur after allogeneic HSCT in approximately 60% to 80% of CMV-seropositive patients without CMV prophylaxis.2,3
- More than 30% of HSCT patients who were CMV-seropositive or had a seropositive donor had CMV infection within 1 month post-transplant.4
Any level of CMV is associated with increased risk of mortality in the first year post-HSCT4,a
CMV viral load as a time-dependent risk factor for overall mortality 1 year after HSCT (n=926)4

CI=confidence interval; HR=hazard ratio.
(a) Results from a large, retrospective, noninterventional cohort study of previously collected CMV viral load and clinical outcome measures (N=1037).4
How could initiation of CMV prophylaxis make a difference for your adult R+ patients?